SCHEMBL1742039

SCHEMBL1742039

CC(CC(c1ccc(C(F)(F)F)cc1)c1ncc(-c2ccc3cnc(F)cc3c2)s1)NC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTPRB P23467 2/20 0.37
CDK2 P24941 3/20 0.36
AKT1 P31749 3/20 0.36
CTSA P10619 1/20 0.36
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
AKR1C3 P42330 2/20 0.34
AKR1C2 P52895 2/20 0.34
FFAR1 O14842 2/20 0.34
ALOX5AP P20292 2/20 0.33
FEN1 P39748 2/20 0.33
S1PR3 Q99500 1/20 0.33
GCGR P47871 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1742500 0.81 CDK2 (0.38) CDK2AKT1CTSAGSK3BDYRK1A
SCHEMBL1742112 0.80 PPARG (0.39) PTPRBCTSAPPARGPPARAS1PR3
SCHEMBL1741924 0.80 CTSA (0.36) CDK2AKT1CTSAGSK3BDYRK1A
SCHEMBL13286160 0.79 AKT1 (0.37) PTPRBCDK2AKT1GSK3BDYRK1A
SCHEMBL1744751 0.77 CDK2 (0.35) PTPRBCDK2AKT1GSK3BDYRK1A
SCHEMBL2544079 0.76 CDK2 (0.36) CDK2AKT1CTSAGSK3BDYRK1A
SCHEMBL2546671 0.76 CDK2 (0.35) PTPRBCDK2AKT1GSK3BDYRK1A
SCHEMBL2549646 0.76 AKT1 (0.42) PTPRBCDK2AKT1GSK3BDYRK1A
SCHEMBL2550295 0.75 AKT1 (0.40) PTPRBCDK2AKT1GSK3BDYRK1A
SCHEMBL2550309 0.75 AKT1 (0.40) PTPRBCDK2AKT1GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2387570-A1 FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2011-11-23 EP disclosed
WO-2010083246-A1 FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-07-22 WO disclosed